Tyra Biosciences Inc at TD Cowen Healthcare Conference Transcript
()-
All right. Good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For our next session, very pleased to have a fireside chat with Tyra, and it's my pleasure to introduce Todd Harris, the CEO. Todd, it's a privilege to have you here. Maybe I'll go ahead and hand it over to you to give a high-level overview of Tyra as it stands today and the various programs.
Thank you, Tyler. It's a pleasure to be here. We're really excited this week, just coming out of our earnings release talking about our Dabo 3x3 strategy. What is that? We have an amazing opportunity with our lead drug, dabogratinib, in 3 potential blockbuster indications moving into phase 3 or pivotal studies, on data that we'll be sharing this year. Upper Tract Urothelial Carcinoma, which is a really high unmet need condition, that involves the kidneys and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
